Τίτλος:
Low-dose IFN-alpha monotherapy in treatment-naive individuals with HIV-1
infection: Evidence of potent suppression of viral replication
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
To evaluate the safety and antiviral action of interferon-alpha
(IFN-alpha) in HIV-1 infection, we undertook a proof of concept study in
27 treatment-naive patients. Eligible patients comprised two groups: the
IFN-alphaT group (n = 17), which received 5 MIU IFN-alpha s.c. daily for
32 consecutive days, and the IFN-alpha NT group (n = 10), which did not
receive IFN-alpha prior to highly active antiretroviral therapy (HAART),
which was commenced on day 28 in both groups. IFN-alpha treatment was
well tolerated in 14 of the 17 patients of the IFN-alphaT group who
completed the study. The mean HIV RNA reduction in the IFN-alphaT group
on day 14 was 1.1 log(10). Viral load suppression was inversely
associated with baseline viral load (p = 0.031). Four weeks after
initiation of HAART, IFN-alphaT and IFN-alpha NT group patients had 2.40
and 1.82 log,() HIV RNA reduction from baseline, respectively (p <
0.001). There was no evidence of cross-resistance with existing
antiretrovirals in patients with HIV-RNA rebound after initial plasma
viral load decline 1 log(10) during IFN-alpha
monotherapy. Thus, low daily IFN-alpha exhibits potent anti-HIV-1
activity in vivo without serious adverse effects. These properties
render IFN-alpha an attractive candidate for further assessment as a
constituent of HAART.
Συγγραφείς:
Hatzakis, A
Gargalianos, P
Kiosses, V
Lazanas, M
Sypsa,
V
Anastassopoulou, C
Vigklis, V
Sambatakou, H
Botsi, C
and Paraskevis, D
Stalgis, C
Περιοδικό:
Journal of Interferon and Cytokine Research
Εκδότης:
MARY ANN LIEBERT INC PUBL
DOI:
10.1089/107999001753238114
